While promising great advancement in the understanding of genetic variability and drug response, the rapidly growing field of pharmacogenomics is plagued with an increasingly complex landscape of intellectual property rights. The often prohibitive transaction costs of negotiating a multitude of licensing agreements threaten to stifle innovation and limit the success that many hope pharmacogenomics will bring to personalized medicine. By aggregating intellectual property rights, patent pools offer an intriguing solution to some of the access issues confronting the pharmacogenomics industry. In the face of a proliferation of genomic patents, patent pools provide a unique opportunity to navigate the patent thicket and render proprietary techno...
Monopolies over many life-saving drugs have led to high prices that remain out of reach for patients...
The various research efforts that comprise the Human Genome Project will inevitably both draw on and...
The biopharmaceutical industry is slowly absorbing the idea of collaborative patent licensing models...
While promising great advancement in the understanding of genetic variability and drug response, the...
While promising great advancement in the understanding of genetic variability and drug response, the...
While promising great advancement in the understanding of genetic variability and drug response, the...
While promising great advancement in the understanding of genetic variability and drug response, the...
The science of pharmacogenetics and pharmacogenomics (or collectively PGx) has advanced rapidly in r...
57-71The field of genomics and systems biology promises to provide unconventional solutions to probl...
As public and private sector initiatives raced to complete the sequence of the human genome, patent ...
The role of patents in personalized medicine is problematic, as the potential market for tailored tr...
The emergence of genetic medicine following decades of molecular biology research has been accompa...
As countries are still in the thick of fighting the COVID-19 health crisis and scientists and pharma...
Pharmacogenomics promises to revolutionize medicine by using genetic information to guide drug thera...
Pharmacogenomics promises to revolutionize medicine by using genetic information to guide drug thera...
Monopolies over many life-saving drugs have led to high prices that remain out of reach for patients...
The various research efforts that comprise the Human Genome Project will inevitably both draw on and...
The biopharmaceutical industry is slowly absorbing the idea of collaborative patent licensing models...
While promising great advancement in the understanding of genetic variability and drug response, the...
While promising great advancement in the understanding of genetic variability and drug response, the...
While promising great advancement in the understanding of genetic variability and drug response, the...
While promising great advancement in the understanding of genetic variability and drug response, the...
The science of pharmacogenetics and pharmacogenomics (or collectively PGx) has advanced rapidly in r...
57-71The field of genomics and systems biology promises to provide unconventional solutions to probl...
As public and private sector initiatives raced to complete the sequence of the human genome, patent ...
The role of patents in personalized medicine is problematic, as the potential market for tailored tr...
The emergence of genetic medicine following decades of molecular biology research has been accompa...
As countries are still in the thick of fighting the COVID-19 health crisis and scientists and pharma...
Pharmacogenomics promises to revolutionize medicine by using genetic information to guide drug thera...
Pharmacogenomics promises to revolutionize medicine by using genetic information to guide drug thera...
Monopolies over many life-saving drugs have led to high prices that remain out of reach for patients...
The various research efforts that comprise the Human Genome Project will inevitably both draw on and...
The biopharmaceutical industry is slowly absorbing the idea of collaborative patent licensing models...